EU support for Malaria Research: from FP6 to FP7

1
EU support for Malaria Researchfrom FP6 to FP7
Rupture of parasite- infected red blood cells

• Andreas Holtel
• Unit F3 Infectious Diseases
• Health Research - EU Commission

2
Malaria - need for research

• Challenges
• Parasite increasingly resistant to drugs
• No malaria vaccine available
• Mosquito vector resistant to insecticides

• Responses
• Basic research on parasite biology, its
  transmission and disease development
• Research to discover, test, develop new
  interventions or improve existing ones drugs,
  vaccines, other control measures

3
Malaria in FP6 2002 - 2006


of 200 million total allocation for EDCTP
programme 40 millions for malaria trials and
malaria research capacity building

• DG Research FP6 total malaria funding 2002-2006
  100 million Euro
• FP6 Large projects on strategic topics,
  partnerships with DCs
• EDCTP programme ph2 ph3 trials in Africa
  incl. capacity building
• EUs spending figure reported in Assessment of
  global investment (
• 6 million for 2004) is grossly incorrect

4
FP6 Structuring European Malaria Research
clinical trials capacity building in Africa
EDCTP
drugs
vaccines
ANTIMAL
EMVDA
BioMalPar
basic research
5
FP6 Structuring European Malaria Research
clinical trials capacity building in Africa
EDCTP
BioMalPar
basic research

• Coordinator Institut Pasteur
• 15.5 million
• 17 European 5 African partners
• basic research into
• 300 publications/y

• parasite genetics
• cell biology metabolism
• pathogenesis
• immunology mosquito vector

6
FP6 Structuring European Malaria Research
EDCTP
ANTIMAL

• Coordinator Liverpool School of
• Tropical Medicine
• 17.5 million
• 27 European 7 African partners
• aminoquinolines, peroxides, lipid
• other targets, natural products ?
• downselection 2-3 candidate drugs

drugs
7
FP6 Structuring European Malaria Research
clinical trials capacity building in Africa
EDCTP
EMVDA

• Coordinator EMVI/SSI Copenhagen
• 13.5 million
• 12 European 6 African partners
• pipeline approach
• ? downselection 2-3 candidates
• vaccines ph1/ph2a trials

vaccines

• candidate vaccines
• platforms adjuvants
• preclinical assays human challenge
• product/clinical development

8
FP6 Structuring European Malaria Research
EDCTP
drugs
vaccines
European Malaria Conference
European Malaria Graduate School
ANTIMAL
EMVDA
Partnerships DC groups
EUs  global players
Platform technologies
Biomalpar
basic research
9
EU Malaria Research the future in FP7

• Malaria remains a major research focus
• Budget for malaria similar to FP6, spread over 7
  years
• Evaluate and consolidate structures arrived at
  under FP6
• Address identified gaps, focussed calls, larger
  structures ? ?
• malaria in pregnancy
• transmission by the mosquito vector
• Intensify collaboration with global players, WHO
  others

10
EU Malaria Research the future under FP7
11
Malaria Research concert of global players
Malaria vaccine funders group with WHO/IVR
EDCTP
DNDi
NIH
MMV
US AID
EU COM
ANTIMAL
EMVI
WHO/TDR
MVI
BioMalPar
Wellcome Trust
WHO/TDR
NIH
MIM
basic research
drugs
vaccines
12
Global Coordination of Malaria Research some
experiences

• Some areas of malaria research more advanced
  vaccines
• Job sharing different organisations with
  different mandates
• Open coordination, loose structures
• WHO as focal point for global coordination
• Include disease-endemic countries at all levels
  incl. governance
• PPPs ideal for focused tasks like product
  development
• EU welcomes global partnerships of national and
  international
• organisations to coordinate global research
  agendas